Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, multi-specialty health care company Allergan
With that in mind, let's take a closer look at Allergan's business and see what CAPS investors are saying about the stock right now.
|Headquarters (founded)||Irvine, Calif. (1948)|
|Market Cap||$29.0 billion|
|Trailing-12-Month Revenue||$5.4 billion|
|Management||Chairman/CEO David Pyott
CFO Jeffrey Edwards
|Return on Equity (average, past 3 years)||10.9%|
|Cash/Debt||$2.6 billion / $1.6 billion|
|Competitors||Bausch & Lomb
Johnson & Johnson
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 94% of the 415 members who have rated Allergan believe the stock will outperform the S&P 500 going forward.
BoTox is a verb and is the only FDA-approved treatment for chronic migraine, which is maybe the #2 or #3 contributor of lost work days in the country. And it actually works. I don't think Allergan can help but grow earnings from here.
If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite a strong four-star rating, Allergan may not be your top choice.
We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2012." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.